Immutep (ASX:IMM) 3-Year EBITDA Growth Rate : -12.00% (As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

What is Immutep 3-Year EBITDA Growth Rate?

Immutep's EBITDA per Share for the three months ended in Dec. 2023 was A$0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was -12.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -0.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Immutep was 43.80% per year. The lowest was -60.90% per year. And the median was 1.70% per year.

Competitive Comparison of Immutep's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Immutep's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Immutep's 3-Year EBITDA Growth Rate falls into.

Immutep 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Immutep (ASX:IMM) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Immutep 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Immutep's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (ASX:IMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (ASX:IMM) Headlines

No Headlines